Catalyst Dossier · compiled by CeliA 🧫

Processa Pharmaceuticals, Inc. (PCSA)

Pharmaceutical Preparations · market cap $6M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-09-15 (est.)Phase 2 · PCS6422 and capecitabineimp 7/10

Pipeline

Asset	Phase	Indication
PCS12852	Phase 2	Gastroparesis
PCS6422 and capecitabine	Phase 2	Breast Cancer
RX-3117	Phase 2	Metastatic Pancreatic Cancer
PCS499	Phase 2	Necrobiosis Lipoidica

Price & technical context

3-month

-20.8%

6-month

+6.1%

12-month

-57.4%

52-wk range

$1.85–$11.97

vs 50-day MA

+8.2%

vs 200-day MA

-29.8%

Realized vol

170.6%

Max drawdown

-96.8%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PCSA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.